Clene Inc. Form 8-K Filing

Clene Inc. entered into a securities purchase agreement on September 15, 2026, with certain existing stockholders, including directors and officers, to issue and sell 1,219,513 shares of common stock at $3.28 per share. The offering is expected to raise approximately $4.0 million in gross proceeds. The company plans to use the net proceeds for general corporate purposes, primarily to support regulatory dialogue and the preparation of regulatory filings and a new drug application for its lead drug candidate, CNM-Au8. This includes funding expanded access protocols, potential future commercialization efforts, and manufacturing expansion. The agreement contains customary representations, warranties, covenants, and conditions to closing. The offering is being made under the company's effective registration statement on Form S-3.